Duration of post-vaccination immunity against yellow fever in adults

Vaccine

Volumn 32, Issue 39, 2014, Pages 4977-4984

  Caldas, Iramaya Rodrigues ^a   Bastos Camacho, Luiz Antonio ^a   Martins Filho, Olindo Assis ^a   de Sousa Maia, Maria de Lourdes ^a   da Silva Freire, Marcos ^b   de Roode Torres, Christiane ^c   de Menezes Martins, Reinaldo ^c   Homma, Akira ^a   Guedes Farias, Roberto Henrique ^c   Yoshida, Anna Maya ^d   Noronha, Tatiana Nogueira ^c   Matos, Eliane Santos ^c   Campos Lemos, Jandira Aparecida ^e   von Doellinger, Vanessa Reis ^f   Simões, Marisol ^c   Bastos, S ^c   da Silva, Ana Maria Basílio ^c   Campos, Elena Cristina Caride Siqueira ^c   de Albuquerque, Elizabeth Maciel ^g   Cruz, João Silveira ^h   da Cunha Junior, Claudemir Francisco ^g   Pimenta, Mauricio ^g   de Souza, Mirian Mariano ^c   de Moraes, Shirley Silva ^c   de Paiva, Maria Camello ^c   de Souza Leite Cruz, Robson ^c   de Sousa Gil, Valéria Lúcia ^c   Pires, Armando ^c   Carvalho, Carolina S ^c   Vieira de Souza, Dayana Cristina ^c   Santos, Jociara Silva ^c   de Oliveira, Luanda Machado ^c   Teixeira Carvalho, Andréa ^a   Campi Azevedo, Ana Carolina ^a   do Valle Antonelli, Lis Ribeiro ^a   Fonseca, Cristina Toscano ^a   Santos, Raiany Araujo ^a   Porto, Luiza Pacheco ^a   Rios, Maria ⁱ   Ribeiro Nogueira, Rita Maria ^k   de Filippis, Ana Maria Bispo ^k   Araújo, Eliane ^a   Pereira, Colonel Jorge Marcelo Rodrigues ^c   Richard Persi, Colonel Harold ^j   de Souza Martins, Major José Ailton ^k   Dornelas Ribeiro, Captain Marcos ^c   de Alcântara Vinhas, Sergeant Aline ^c   Rocha Alves, Sergeant Tatiane ^l   e Ribeiro, Aparecida Azola Costa Ribeiro ^c   Esteves, Cynthia ^c   Bianchini, Cyomara de Jesus ^c   Cabral, Thiago Campos ^c   Cotta Malaquias, Luiz Cosme ^m   Tauil, Pedro Luiz ⁿ   da Costa Vasconcelos, Pedro Fernando ^o   more..

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b Development Christiane de Roode Torres MD ASCLIN (at the time of thestudy)   (Brazil)

^c Laboratory of Biomarkers forDiagnostics and Monitoring Laboratório de Biomarcadores deDiagnóstico e Monitorac ão LBDM) René Rachou ResearchCenter Fiocruz ^*

^d Laboratory of Viral Technology Labo ratório de Tecnologia Virológica Latev   (Brazil)

^e State Department ofHealth of Minas Gerais   (Brazil)

^f Centre for Statistics AsclinMarisol Simões LATEV   (Brazil)

^g Centre for Statistics   (Brazil)

^h Laboratory of Serology Superintendency for the Control of Endemies   (Brazil)

ⁱ CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^j Clinical Studies on Vaccines Asclin ^*  (Brazil)

^k Sub commanderof the Airborne Infantry Battalion Health Unit Airborne InfantryBattalion Brazilian Army   (Brazil)

^l Laboratory of Immunol ogy IBEX Brazilian Army   (Brazil)

^m FEDERAL UNIVERSITY OF ALFENAS   (Brazil)

ⁿ UNIVERSITY OF BRASILIA   (Brazil)

^o INSTITUTO EVANDRO CHAGAS   (Brazil)

more..

Author keywords

Immunogenicity; Vaccination policy; Yellow fever vaccine

Indexed keywords

IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; YELLOW FEVER VACCINE; BACTERIUM ANTIBODY;

ADULT; AGED; ARTICLE; BRAZIL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DENGUE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; REVACCINATION; VACCINATION; VERY ELDERLY; YELLOW FEVER; YOUNG ADULT; ADOLESCENT; ANTIBODY PRODUCTION; BLOOD; EPIDEMIOLOGY; IMMUNIZATION; TIME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, BACTERIAL; ANTIBODIES, NEUTRALIZING; ANTIBODY FORMATION; BRAZIL; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; SEROEPIDEMIOLOGIC STUDIES; TIME FACTORS; YELLOW FEVER; YELLOW FEVER VACCINE; YOUNG ADULT;

EID: 84906099616     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.07.021     Document Type: Article

References (22)

1. Vasconcelos P.F.C. Febre Amarela. Rev Soc Bras Med Trop 2003, 36(2):275-293.
2. World Health Organization International health regulations 2005, Available at: http://www.who.int/ihr/9789241596664/en/index.html, http://www.who.int/ith/updates/20140605/en/.
3. Brazil Ministério da Saúde. Secretaria de Vigilância em Saúde. Guia de vigilância epidemiológica 2005, 816. Ministério da Saúde [Ministry of Health], Brasília, Série A. Normas e Manuais Técnicos [A Series. Technical Manuals and Norms]. 6th ed.
4. World Health Organization Vaccines and vaccination against yellow fever. WHO position paper - June 2013. Wky Epidemiol Rec 2013, 88:269-284.
5. World Health Organization Meeting of the Strategic Advisory Group of Experts on immunization, April 2013 - conclusions and recommendations. Wky Epidemiol Rec 2013, 88:201-216.
6. World Health Organization Yellow fever vaccine. WHO position paper. Wky Epidemiol Rec 2003, 78(October (40)). 349e59.
7. Gotuzzo E., Yactayo S., Córdova E. Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years. Am J Trop Med Hyg 2013, 89:434-444.
8. Simoes M., Camacho L.A.B., Yamamura A.M.Y., Miranda E.H., Cajaraville A.C.R.A., Freire M.S. Evaluation of accuracy and reliability of the plaque reduction neutralization test (micro-PRNT) in detection of yellow fever virus antibodies. Biologicals 2012, 40:399-404.
9. Nogueira R.M.R., Schatzmayr H.G., Miagostovich M.P., Cavalcanti S.M.B., Carvalho R. Use of MAC-ELISA for evaluation of yellow fever vaccination. Rev Inst Med Trop São Paulo 1992, 34(5):447-450.
10. Nogueira R.M.R. Diagnóstico Laboratorial Específico e Diagnóstico Imunológico da Dengue 2008, 97-108. Dengue Diagnóstico, Tratamento e Prevenção [Dengue Diagnosis, Treatment and Prevention], Editora Rubio Ltda. 2nd ed.
11. Monath T.P., Gershman M., Staples J.E., Barrett A.D.T. Yellow fever vaccine. Vaccines 2013, Elsevier Saunders Inc, [Chapter 38]. 6th ed. S.A. Plotkin, W.A. Orenstein, P.A. Offit (Eds.).
12. Abramson J.H. WINPEPI updated: computer programs for epidemiologists, and their teaching potential. Epidemiol Perspect Innov 2011, 8:1.
13. Patel D., Simons H. Yellow fever vaccination: is one dose always enough?. Travel Med Infect Dis 2013, 11:266-273.
14. Grobusch M.P., Goorhuis A., Wieten R.W., Verberk J.D., Jonker E.F., van Genderen P.J., et al. Yellow fever re-vaccination guidelines change-a decision too feverish?. Clin Microbiol Infect 2013, 19(10):885-886.
15. Camacho L.A.B., Freire M.S., Leal M.L.F., Aguiar S.G., Nascimento J.P., Iguchi T., et al. Immunogenicity of WHO-17D and Brazilian 17DD yellow fever vaccines: a randomized trial. Rev Saúde Públ 2004, 38(5):671-678.
16. Gómez S.Y., Ocazionez R.E. Anticuerpos Neutralizantes contra el Virus de la Fiebre Amarilla 17 D en Colombianos Vacunados y no Vacunados con Inmunidad a Dengue. Rev Salud Públ 2008, 10(5):796-807.
17. Fox J.P., Da Cunha J.F., Kossobudzki S.L. Additional observations on the duration of humoral immunity following vaccination with the 17d strain of yellow fever virus. Am J Hyg 1948, 47:64-70.
18. Niedrig M., Lademann M., Emmerich P., Lafrenz M. Assessment of IgG antibodies against yellow fever virus after vaccination with 17D by different assays: neutralization test, haemagglutination inhibition test, immunofluorescence assay and ELISA. Trop Med Int Health 1999, 4(12):867-871.
19. Bodilis H.C., Benabdelmoumen G., Gergely A., Goujon C., Pelicot M.P., Poujol Consigny P.H.L. Persistance à long terme des anticorps neutralisants de la chez les personnes fièvre jaune âgées 60 ans et plus. Bull Soc Pathol Exot 2011, 104:260-265.
20. Melo A.B., Silva M.P.C., Magalhães M.C.F., Gil L.H.V.G., Carvalho E.M.F., Braga-Neto U., et al. Description of a prospective 17DD yellow fever vaccine cohort in Recife, Brazil. Am J Trop Med Hyg 2011, 85(4):739-747.
21. Rosenzweig E.C., Babione R.W., Wisseman C.L. Immunological studies with group B arthropod-borne viruses. IV: Persistence of yellow fever antibodies following vaccination with 17D strain yellow fever vaccine. Am J Trop Med Hyg 1963, 12:230-265.
22. Martins R.M., Maia M.L.S., Farias R.H.G., Camacho L.A.B., Freire M.S., Galler R., et al. 17DD yellow fever vaccine: a double-blind, randomized clinical trial of immunogenicity and safety on a dose-response study. Hum Vaccine Immunother 2013, 9:1-10.